Aja Beckett quit her job after her weight-loss shot-tracking app, Shotsy, took off on Reddit.
Sales of Eli Lilly’s (LLY) blockbuster weight-loss drug Zepbound surged in the fourth quarter despite missing the company’s initial sales expectations. Zepbound sales reached $1.9 billion in ...
For example, Wegovy (a GLP-1 receptor agonist) and Zepbound (a dual agonist) are both FDA-approved specifically to treat weight loss, while Ozempic (another GLP-1 receptor agonist) is not FDA ...
In the glittering world of celebrity-endorsed weight loss transformations and viral before-and-after photos, a darker narrative is emerging from the shadows ...
Eli Lilly investors and analysts said they want to hear details from the company on how exactly it plans to grow U.S. sales ...
Compounding pharmacies aren’t the only makers of off-brand versions of Novo Nordisk’s Wegovy and Eli Lilly’s Zepbound. The ...
People taking weight-loss drugs say they are losing their sight. Science is trying to figure out why
open image in gallery A small percentage of patients taking weight loss and diabetes drugs like Ozempic and Zepbound have experienced vision loss. However, scientists they there is not an ...
Eli Lilly & Co. said Thursday that its Type 2 diabetes drug Mounjaro and its weight-loss and diabetes drug Zepbound drove a 45% increase in fourth-quarter revenue to $13.53 billion. The drugmaker ...
Investors are upset at a lack of clarity over the results of Wegovy successor CagriSema after trials published in December.
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback